• Cresco Labs published quarterly MD&A covering three months ended March 31, 2026, showing revenue of USD 151.33 million versus USD 165.76 million a year earlier; net loss widened to USD 17.01 million from USD 15.23 million.
• Pricing pressure in Illinois, disruption in Michigan, reduced California operations weighed on sales; wholesale growth in Massachusetts, Ohio retail growth partly offset decline.
• Gross profit fell to USD 75.45 million from USD 78.63 million; gross margin rose to 49.9% from 47.4% on mix shift toward higher-margin states, supported by operational efficiencies.
• Adjusted EBITDA slipped to USD 32.9 million from USD 36.23 million; operating cash flow swung to USD 5.6 million used from USD 30.5 million provided, driven by lower gross profit, interest payments, inventory build, vendor timing.
• Expansion pipeline included conditional award of Texas Compassionate Use Program license; agreements signed to acquire 4 dispensaries for estimated USD 14.7 million, plus purchase agreement pending approval for 9 dispensaries with estimated USD 50 million consideration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cresco Labs Inc. published the original content used to generate this news brief on May 08, 2026, and is solely responsible for the information contained therein.